Literature DB >> 35864888

Pathophysiology, Diagnosis, and Management of Coronary No-Reflow Phenomenon.

Gagan Kaur1, Patrick Baghdasaryan1, Balaji Natarajan1, Prabhdeep Sethi1, Ashis Mukherjee1, Padmini Varadarajan1, Ramdas G Pai1.   

Abstract

Coronary no-reflow phenomenon is a lethal mechanism of ongoing myocardial injury following successful revascularization of an infarct-related coronary artery. Incidence of this phenomenon is high following percutaneous intervention and is associated with adverse in-hospital and long-term outcomes. Several mechanisms such as ischemia-reperfusion injury and distal microthromboembolism in genetically susceptible patients and those with preexisting endothelial dysfunction have been implicated. However, the exact mechanism in humans is still poorly understood. Several investigative and treatment strategies within and outside the cardiac catheterization laboratory have been proposed, but they have not uniformly shown success in reducing mortality or in preventing adverse left ventricular remodeling resulting from this condition. The aim of this article is to provide a brief and concise review of the current understanding of the pathophysiology, clinical predictors, and investigations and management of coronary no-reflow phenomenon. International College of Angiology. This article is published by Thieme.

Entities:  

Keywords:  angiogram; cardiac MRI; diagnosis; management; myocardial blush score; no-reflow phenomenon; treatment

Year:  2022        PMID: 35864888      PMCID: PMC9296268          DOI: 10.1055/s-0041-1735949

Source DB:  PubMed          Journal:  Int J Angiol        ISSN: 1061-1711


  35 in total

1.  Impact of intracoronary adenosine administration during primary PCI: A meta-analysis.

Authors:  Alberto Polimeni; Salvatore De Rosa; Jolanda Sabatino; Sabato Sorrentino; Ciro Indolfi
Journal:  Int J Cardiol       Date:  2015-11-18       Impact factor: 4.164

Review 2.  The no-reflow phenomenon: State of the art.

Authors:  Claire Bouleti; Nathan Mewton; Stéphane Germain
Journal:  Arch Cardiovasc Dis       Date:  2015-11-23       Impact factor: 2.340

3.  A randomized, double-blinded, placebo-controlled multicenter trial of adenosine as an adjunct to reperfusion in the treatment of acute myocardial infarction (AMISTAD-II).

Authors:  Allan M Ross; Raymond J Gibbons; Gregg W Stone; Robert A Kloner; R Wayne Alexander
Journal:  J Am Coll Cardiol       Date:  2005-06-07       Impact factor: 24.094

Review 4.  Adenosine and verapamil for no-reflow during primary percutaneous coronary intervention in people with acute myocardial infarction.

Authors:  Qiang Su; Tun Swe Nyi; Lang Li
Journal:  Cochrane Database Syst Rev       Date:  2015-05-18

5.  Intracoronary versus intravenous bolus abciximab during primary percutaneous coronary intervention in patients with acute ST-elevation myocardial infarction: a randomised trial.

Authors:  Holger Thiele; Jochen Wöhrle; Rainer Hambrecht; Harald Rittger; Ralf Birkemeyer; Bernward Lauer; Petra Neuhaus; Oana Brosteanu; Peter Sick; Marcus Wiemer; Sebastian Kerber; Klaus Kleinertz; Ingo Eitel; Steffen Desch; Gerhard Schuler
Journal:  Lancet       Date:  2012-02-21       Impact factor: 79.321

6.  Regional heterogeneity of human myocardial infarcts demonstrated by contrast-enhanced MRI. Potential mechanisms.

Authors:  J A Lima; R M Judd; A Bazille; S P Schulman; E Atalar; E A Zerhouni
Journal:  Circulation       Date:  1995-09-01       Impact factor: 29.690

7.  The clinical implications of no reflow demonstrated with intravenous perfluorocarbon containing microbubbles following restoration of Thrombolysis In Myocardial Infarction (TIMI) 3 flow in patients with acute myocardial infarction.

Authors:  T R Porter; S Li; R Oster; U Deligonul
Journal:  Am J Cardiol       Date:  1998-11-15       Impact factor: 2.778

8.  The effect of verapamil on the restoration of myocardial perfusion and functional recovery in patients with angiographic no-reflow after primary percutaneous coronary intervention.

Authors:  Shigeo Umemura; Seishi Nakamura; Tetsuro Sugiura; Yoshiaki Tsuka; Keisuke Fujitaka; Susumu Yoshida; Masato Baden; Toshiji Iwasaka
Journal:  Nucl Med Commun       Date:  2006-03       Impact factor: 1.690

9.  Incidence and outcomes of no-reflow phenomenon during percutaneous coronary intervention among patients with acute myocardial infarction.

Authors:  Robert W Harrison; Atul Aggarwal; Fang-shu Ou; Lloyd W Klein; John S Rumsfeld; Matthew T Roe; Tracy Y Wang
Journal:  Am J Cardiol       Date:  2012-10-27       Impact factor: 2.778

Review 10.  The predictors of no reflow phenomenon after percutaneous coronary intervention in patients with ST elevation myocardial infarction: A meta-analysis.

Authors:  Jonny Karunia Fajar; Teuku Heriansyah; Mohammad Saifur Rohman
Journal:  Indian Heart J       Date:  2018-01-31
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.